Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders
M Mané-Damas, PC Molenaar, P Ulrichts… - Autoimmunity …, 2022 - Elsevier
The presence of autoantibodies directed against the muscle nicotinic acetylcholine receptor
(AChR) is the most common cause of myasthenia gravis (MG). These antibodies damage …
(AChR) is the most common cause of myasthenia gravis (MG). These antibodies damage …
Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
J Du, J Zhuang - Chronic Diseases and Translational Medicine, 2021 - mednexus.org
Treatment of multiple myeloma (MM) has advanced dramatically in the past two decades.
However, under the conditions of the COVID-19 pandemic, treatment strategies have been …
However, under the conditions of the COVID-19 pandemic, treatment strategies have been …
[HTML][HTML] Multilevel Mechanisms of Cancer Drug Resistance
M Roszkowska - International journal of molecular sciences, 2024 - mdpi.com
Cancer drug resistance represents one of the most significant challenges in oncology and
manifests through multiple interconnected molecular and cellular mechanisms. Objective: To …
manifests through multiple interconnected molecular and cellular mechanisms. Objective: To …
[HTML][HTML] A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
V Raimondi, NT Iannozzi… - … of Targeted Anti …, 2022 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is a blood cancer that derives from plasma cells (PCs), which will
accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat …
accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat …
Real world M³P Panel-Sequenzierung für die personalisierte Therapie des Multiplen Myeloms
K Dereser - 2024 - opus.bibliothek.uni-wuerzburg.de
Obwohl es in den letzten 10-15 Jahren gelang, multiple MM-Genome mittels NGS auf eine
kosteneffiziente Art und mit geringem Zeit-und Materialaufwand zu sequenzieren und …
kosteneffiziente Art und mit geringem Zeit-und Materialaufwand zu sequenzieren und …
The roles of TRAF3 mutation in the oncogenic progression and drug response of multiple myeloma
SA Neja - Genome Instability & Disease, 2020 - Springer
Multiple myeloma (MM) is a malignant plasma cell proliferating in the bone marrow.
Oncogenesis of MM is a multi-stage cytogenetic event. Among these, aberrant activation of …
Oncogenesis of MM is a multi-stage cytogenetic event. Among these, aberrant activation of …
[引用][C] Real World Next Generation M³P-Panel-Sequenzierung für die personalisierte Therapie des Multiplen Myeloms
K Dereser